Latest available resultsQuarter ended June 30, 202610-Q · August 7, 2026
Filed with the SECMerck & Co., Inc.
MRKPharma & biotech
Next reportOctober 29, 2026Analyst forecast 2.237 $/share
Revenue
$16.61B
▲ +5.1% vs prior year% YoY
Net income
−$1.33B
▼ -130.2% vs prior year% YoY
EPS
-0.54$
▼ -130.7% vs prior year% YoY
Net margin
-8.0%
▼ -36.0 percentage points vs prior year pp YoY
Revenue▲ +5.1 %
Margins (% of revenue)GrossOperating N/ANet
Net income▼ -130.2 %
EPS▼ -130.7 %
View financial tableQuarter ended June 30, 2026
| Metric | Value | Context |
|---|---|---|
| Operations | ||
| Revenue | $16.61B | |
| Gross profit | $12.21B | 73.5 % |
| Operating income | — | never filed |
| Net income | −$1.33B | -8.0 % |
| R&D | $9.74B | 58.7 % |
| EPS (diluted) | -0.54 $ | |
| Balance sheet | ||
| Assets | $129.80B | |
| Liabilities | $87.82B | |
| Equity | $41.98B | |
| Cash | $6.85B | |
| Capital | ||
| Shares outstanding | 2.47B | as of 2026-07-31 |
| Public float | — | |